Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 467 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention... April 29, 2025 Why Wearing Comfortable Clothes During Cancer Treatment Matters October 21, 2021 Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer October 6, 2021 Two Women With Terminal Breast Cancer Started A Podcast That’s Unflinchingly... November 15, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory... Glucose Control Key in Reducing Cancer Risk for People with Type... How Being an Athlete Prepared Me for My Cancer Experience FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer
